drugset / Trial / NCT03009058
Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type. The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.
Timeline
- Start
- 2017-05-31
- Primary completion
- 2017-08-30
- Completion
- 2017-08-30
Outcome
Outcome not reported
Stopped: “Commercial reasons”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-101 | Other / unclassified | — | — |
| Background | Capecitabine | Small molecule | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Ipilimumab | Monoclonal antibody | — | — |
| Background | Irinotecan | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
| Background | fluorouracil | Small molecule | — | — |